Hundreds of millions of dollars of allegedly improper payments under review by China’s police. Evidence of sexual favours allegedly exchanged as part of an elaborate scheme to boost sales and profits in the world’s fastest-growing drug market. It was not what GlaxoSmithKline, the UK pharmaceuticals group rebuilding its image after past scandals, wanted to hear.
對于身陷多起丑聞后正努力重塑自身形象的葛蘭素史克（GlaxoSmithKline，簡稱GSK）來說，它在中國陷入的麻煩恐怕是它此刻最不想面對的——數億美元資金往來涉嫌不當支付，正被中國警方調查；還有證據顯示，它為了提升在中國這個全球增長最快的藥品市場中的銷售額，不惜采取激進手段，甚至涉嫌接受性賄賂。
您已閱讀8%（513字），剩余92%（5974字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。